First-in-human trial shows safety and efficacy of CAR T cell therapy for advanced prostate cancer

Treating prostate cancer with immunotherapy is currently difficult to do. But results from a first in-human phase 1 trial using a chimeric antigen receptor (CAR) T cell therapy developed by researchers from City of Hope®, one of the largest cancer research and treatment organizations in the United States, showed that patients with advanced prostate cancer can be treated safely with the cellular immunotherapy with promising therapeutic activity, according to the phase 1 trial study published today in Nature Medicine.

The trial treated 14 prostate stem cell antigen (PSCA)-positive patients who had metastatic castration resistant prostate cancer (mCRPC), which had spread beyond the prostate and no longer responded to hormone treatment, using CAR T cell therapy. More than 34,000 men with this type of prostate cancer die each year in the United States.

Saul Priceman, Ph.D., City of Hope associate professor, Department of Hematology & Hematopoietic Cell Transplantation, and team developed CAR T cells that target prostate stem cell antigen (PSCA) found to be highly expressed in prostate cancer. The treatment took a patient's immune cells – known as T cells – from the bloodstream, and reprogrammed the cells in a laboratory with a CAR to recognize and attack the PSCA protein on the surface of cancer cells. CAR T cells were then infused back into the patient's system to destroy cancer cells.

Prostate cancer has been called an immune desert -; the tumor microenvironment is difficult to treat with immunotherapies because you don't get a lot of T cells inside the tumor. It takes something really powerful to overcome that. Our study showed that City of Hope's CAR T cell therapy for prostate cancer could be a step closer to doing that."

Tanya Dorff, M.D., City of Hope section chief, Genitourinary Disease Program, and professor, Department of Medical Oncology & Therapeutics Research

"Our trial's major finding is that PSCA-directed CAR T cells are safe and do work against mCRPC," Priceman added. "This opens up the opportunity to continue to develop this type of cellular immunotherapy for these patients, who currently have no other effective treatment options."

The trial's goals were to examine the therapy's safety and dose-limiting toxicities, or side effects that limit the amount of treatment that can be administered, as well as preliminary data on the treatment's efficacy in patients.

The study's findings were:

  • Patients received a single infusion of 100 million CAR T cells without prior lymphodepletion chemotherapy, which is used routinely in blood cancers to improve the efficacy of CAR T cell treatment. Since this was a first-in-human CAR T cell trial, it was important to assess the safety of CAR T cells alone in patients.
  • At that same CAR T cell dose and with lymphodepletion, there was a side effect of dose-limiting toxicity of cystitis, or irritation of the bladder. Dorff explained that PSCA is also found in the bladder so the CAR T cells most likely attacked the bladder cells, causing inflammation. Researchers then added a new cohort to the study using reduced lymphodepletion, which mitigated this toxicity.
  • Four out of 14 patients had declines in their PSA levels, which is a serum marker of disease progression in people with prostate cancer, including one patient with a significant decline. Imaging showed therapeutic responses in a subset of treated patients.
  • Five out of 14 patients had mild or moderate cytokine release syndrome, which can be caused by a large, rapid release of cytokines into the blood from immune cells and is a common side effect after CAR T cell therapy. CRS was a treatable side effect.
  • CAR T cells did not persist at high levels beyond the 28-day monitoring period, which limits the therapy's effectiveness. This presented a common challenge in the solid tumor CAR T cell field that researchers plan to address in a follow-up City of Hope trial using the therapy that is now open for enrollment.

One patient who had received several prior therapies responded well to the CAR T cell therapy. His PSA level decreased by 95% and cancer in his bones and soft tissue also declined. He experienced this positive response for approximately eight months.

"The patient's results were very encouraging, and we are deeply grateful for his participation in our study as well as other patients and their families," Dorff said. "We want to continue with this therapy and increase the amount of CAR T cells, and continue to carefully monitor for any health problems, as we think this can improve the therapy's effectiveness."

The phase 1b trial using the PSCA-CAR T cell therapy in combination with radiation to enhance anti-tumor activity aims to enroll up to 24 patients.

City of Hope, a recognized leader in CAR T cell therapies, has treated nearly 1,500 patients since its CAR T program started in the late 1990s. The institution continues to have one of the most comprehensive CAR T cell clinical research programs in the world -; it currently has about 70 ongoing CAR T clinical trials, which include 13 different solid tumor types. The trials use City of Hope-developed therapies and industry-sponsored products. A recent study published in Nature Medicine featured City of Hope's CAR T cell therapy for brain tumors.

City of Hope manufactured the CAR T cells in its own facility, the Cell Therapy Production Center on its Los Angeles campus.

The Prostate Cancer Foundation helped fund the trial.

Source:
Journal reference:

Dorff, T. B., et al. (2024). PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nature Medicine. doi.org/10.1038/s41591-024-02979-8.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study: Women with severe endometriosis 10 times more likely to get ovarian cancer